Compare Vanguard Mega Cap Growth ETF (MGK) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Novavax Inc — how do they compare? Vanguard Mega Cap Growth ETF trades at $94.22 (market cap $33.70B), while Novavax Inc trades at $12 (market cap $1.82B). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 18.5× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 1,362,010). Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and Novavax Inc for 59 Days on average.
| MGK | NVAX | |
|---|---|---|
Market Cap | $33.70B | $1.82B |
Volume | 1,362,010 | 6,198,505 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $12.56 |
52-Week Low | $70.70 | $6.22 |
Typical Hold Time | 45 Days | 59 Days |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK trades at $94.92, down 0.2% on the day, with a bullish technical signal from moving averages but bearish momentum from oscillators. The ETF focuses on large-cap US growth stocks with heavy technology concentration, offering low 0.05% expense ratio exposure to companies like Nvidia, Apple, and Microsoft. Recent articles highlight its strong five-year performance and appeal for long-term growth investors seeking mega-cap stability.
MGK presents a compelling growth ETF option with concentrated mega-cap exposure, though its tech-heavy composition increases sector-specific risk. The fund's low costs and historical outperformance make it suitable for investors with higher risk tolerance, while current technical indicators suggest potential near-term consolidation after recent gains.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
